Andrew Hirsch - 15 Feb 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: President & CEO, Director
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 15 Feb 2023
Transactions value $: $0
Form type: 4
Filing time: 15 Feb 2023, 15:44:26 UTC
Previous filing: 01 Feb 2023
Next filing: 05 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+81.6K	+302.16%	$0.00	109K	15 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+367K		$0.00	367K	15 Feb 2023	Common Stock	367K	$5.77	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 15, 2024.
F2	The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 15, 2023.